COVID-19-induced silent myocarditis and newly developed hypertension in a 3-year-old boy

Elaheh Malakan Rad1, Sara Momtazmanesh2

  • 1Department of Pediatric Cardiology, Children's Medical Center (Pediatric Center of Excellence), Tehran University of Medical Sciences, Tehran, Iran. erad@tums.ac.ir.

Insights

This case study highlights a rare instance of silent COVID-19 myocarditis in a child, leading to dilated cardiomyopathy and new-onset hypertension. Early cardiac evaluation and blood pressure monitoring are crucial for children with COVID-19.

Area of Science:

  • Pediatric Cardiology
  • Infectious Diseases
  • Cardiovascular Imaging

Background:

  • COVID-19 myocarditis affects 7-28% of hospitalized patients, potentially leading to fulminant myocarditis or dilated cardiomyopathy.
  • While dilated cardiomyopathy post-COVID-19 has been noted in children, silent cases progressing to this condition are unreported.
  • Newly developed hypertension post-COVID-19 is documented in adults, but not previously in children.

Purpose of the Study:

  • To report the first case of silent COVID-19 myocarditis progressing to dilated cardiomyopathy and newly developed systemic hypertension in a pediatric patient.
  • To emphasize the importance of cardiac evaluation and blood pressure monitoring in children following SARS-CoV-2 infection.

Main Methods:

  • A 3-year-old boy with respiratory distress was evaluated after a history of SARS-CoV-2 infection.
  • Echocardiography revealed severe left ventricular systolic dysfunction consistent with dilated cardiomyopathy.
  • Cardiac magnetic resonance imaging confirmed myocarditis; treatment with inotropic support showed no improvement.

Main Results:

  • The patient presented with symptoms indicative of dilated cardiomyopathy and myocarditis.
  • Despite initial treatment, left ventricular function did not improve, necessitating transfer for advanced cardiac support.
  • The case demonstrates a progression from silent COVID-19 myocarditis to dilated cardiomyopathy and new-onset hypertension.

Conclusions:

  • COVID-19 can induce silent myocarditis, potentially progressing to dilated cardiomyopathy and systemic hypertension in children.
  • Mandatory cardiac assessment and blood pressure measurement are recommended for all children with COVID-19.
  • Cardiac MRI, strain imaging (apical rocking, prestretch-rebound stretch), and M-mode echocardiography (septal flash) are valuable diagnostic and prognostic tools.
Abstract

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
64
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
71
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
99
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
34
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
36
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
24